This was done by quantifying the GPX1 levels in tissue cores obtained from 200 prostate cancer patients who experienced biochemical recurrence (rising PSA levels) and 200 matched control patients whose cancers did not return, by immunohistochemistry. This evidence concerns the gene KLK3 and prostate carcinoma.